Deleterious BRCA1/2 mutations in an urban population of Black women

Breast Cancer Research and Treatment

Volumn 153, Issue 1, 2015, Pages 201-209

  Lynce, Filipa ^a   Smith, Karen Lisa ^b   Stein, Julie ^c   DeMarco, Tiffani ^d   Wang, Yiru ^e   Wang, Hongkun ^e   Fries, Melissa ^f   Peshkin, Beth N ^g   Isaacs, Claudine ^g  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d INOVA FAIRFAX HOSPITAL   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f WASHINGTON HOSPITAL CENTER   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

Author keywords

Black women; BRCA mutations; Breast cancer; Genetic testing

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEALTH INSURANCE; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; URBAN POPULATION; YOUNG ADULT; BLACK PERSON; DISTRICT OF COLUMBIA; ETHNOLOGY; GENETICS; HEALTH SURVEY; MUTATION; PROGNOSIS; REGISTER; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; DISTRICT OF COLUMBIA; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC TESTING; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; MIDDLE AGED; MUTATION; POPULATION SURVEILLANCE; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS; URBAN POPULATION; YOUNG ADULT;

EID: 84939252201     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3527-8     Document Type: Article

References (38)

1. Bauer KR, Brown M, Cress RD (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728
2. Kwan ML, Kushi LH, Weltzien E et al (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11(3):R31. doi:10.1186/bcr2261
3. Peshkin BN, Alabek ML, Isaacs C (2010) BRCA1/2 mutations and triple negative breast cancers. Breast Dis 32(1–2):25–33
4. Young SR, Pilarski RT, Donenberg T et al (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86. doi:10.1186/1471-2407-9-86
5. Atchley DP, Albarracin CT, Lopez A et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282–4288
6. Couch FJ, Hart SN, Sharma P et al (2015) Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 33:304–311
7. Althuis MD, Brogan DD, Coates RJ (2003) Breast cancers among very young premenopausal women (United States). Cancer Causes Control 14(2):151–160
8. Pal T, Bonner D, Kim J et al (2013) Early onset Breast Cancer in a Registry-based sample of African-American women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. Breast J 19(2):189–192
9. John EM, Miron A, Gong G et al (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 U.S. racial/ethnic groups. JAMA 298(24):2869–2876
10. Malone KE, Daling JR, Doody DR et al (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66(16):8297–8308
11. Haffty BG, Silber A, Matloff E et al (2006) Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J Med Genet 43:133–137
12. Nanda R, Schumm LP, Cummings S et al (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294(15):1925–1933
13. Hall MJ, Reid JE, Burbidge LA et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115(10):2222–2233
14. Judkins T, Rosenthal E, Arnell C et al (2012) Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer 118(21):5210–5216
15. Greenup R, Buchanan A, Lorizio W et al (2013) Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 20(10):3254–3258
16. ®). Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2015. www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf, Accessed 8 July 2015
17. Stuckey A, Febbraro T, Laprise J, et al (2014) Adherence patterns to National Comprehensive Cancer Network Guidelines for referral of women with breast cancer to genetics professionals. Am J Clin Oncol 2014 [Epub ahead of print]
18. Pal T, Bonner D, Cragun D et al (2014) BRCA sequencing and large rearrangement testing in young Black women with breast cancer. J Commun Genet 5(2):157–165
19. Stoppa-Lyonnet D, Laurent-Puig P, Essioux L et al (1997) BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 60(5):1021–1030
20. Shatavi SV, Dohany, L, Chisti MM, et al. (2013) Unique genetic characteristics of BRCA mutation carriers in a cohort of Arab American women. J Clin Oncol 31, (suppl;aabstr 1541)
21. Eggington JM, Burbidge LA, Roa B, et al (2012) Current variant of uncertain significance rates in BRCA1/2 and Lynch syndrome testing (MLH1, MSH2, MSH6, PMS2, EPCAM) American College of Medical Genetics and Genomics annual meeting, Charlotte
22. Ricker CN, Sturgeon JD, Gruber SB (2014) Mutation and uncertain variant findings in ethnic minority patients undergoing multi-gene panel testing for cancer risk assessment at a safety-net public hospital (Abstract 3428S). Presented at the 64th Annual Meeting of the American Society of Human Genetics, on October 2014 in San Diego
23. LaDuca H, Stuenkel AJ, Dolinsky JS et al (2014) Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Gene Med 16(11):830–837
24. Tung N, Battelli C, Allen B et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121(1):25–33
25. Schwartz MD, Isaacs C, Graves KD et al (2012) Long-term outcome of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 118(2):510–517
26. Bradbury AR, Comfort NI, Dignam JJ et al (2008) Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 10:161–166
27. Kinney AY, Simonsen SE, Baty BJ (2006) Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred. J Genet Couns 15:293–305
28. Salant T, Ganschow PS, Olopade OI (2006) ”Why take it if you don’t have anything?” breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med 21:779–785
29. Thompson HS, Sussner K, Schwartz MD et al (2012) Receipt of genetic counseling recommendations among black women at high risk for BRCA mutations. Genet Test Molec Biomark 16(11):1257–1262
30. Halbert CH, Brewster K, Collier A et al (2005) Recruiting African American women to participate in hereditary breast cancer research. J Clin Oncol 23(31):7967–7973
31. Glenn BA, Chawla N, Bastani R (2012) Barriers to genetic testing for breast cancer risk among ethnic minority women: an exploratory study. Ethn Dis 22(3):267–273
32. Susswein LR, Skrzynia C, Lange LA et al (2008) Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer. J Clin Oncol 26:32–36
33. Sussner KM, Edwards TA, Thompson HS et al (2011) Ethnic, racial and cultural identity and perceived benefits and barriers related to genetic testing for breast cancer among at-risk women of African descent in New York City. Public Health Genomics 14(6):356–370
34. Armstrong K, Putt M, Halbert CH et al (2012) The influence of health care policies and health care system disrupt on willingness to undergo genetic testing. Med Care 50(5):381–387
35. Affordable Care Act Implementation FAQs–Set 12. http://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs12.html. Accessed on April 15 2015
36. Churpek JE, Walsh T, Zheng Y et al (2015) Inherited predispostion to breast cancer among African American women. Breast Cancer Res Treat 149(1):31–39
37. Heikkinen T, Kärkkäinen H, Aaltonen K et al (2009) The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 15(9):3214–3222
38. Antoniou AC, Casadei S, Heikkinen T et al (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371(6):497–506